{"_id": "650d0d33c9669d2e208ec2c9", "Not yet fixed MQL": "{\n\"and\": [\n{\n\"$and\": [\n{\"prostate cancer histology\": \"adenocarcinoma of the prostate without small cell histology\"},\n{\"prostate cancer progression on androgen deprivation therapy\": true},\n{\"metastatic disease\": true},\n{\n\"$or\": [\n{\"abiraterone acetate exposure\": \"abiraterone-na\u00efve\"},\n{\"abiraterone acetate exposure\": \"received prior abiraterone acetate for the treatment of mHSPC or mCRPC, for a minimum of 4 weeks and not progressed while on treatment\"},\n{\"abiraterone acetate exposure\": \"received prior abiraterone acetate for the treatment of mHSPC or mCRPC and progressed on treatment after a minimum of 8 weeks treatment (minimum 14 weeks for those with bone progression)\"}\n]\n},\n{\"androgen deprivation\": true},\n{\"bone resorptive therapy\": true},\n{\n\"$and\": [\n{\"refrain from donating sperm\": true},\n{\n\"$or\": [\n{\"be abstinent\": true},\n{\"must agree to use male condom\": true}\n]\n}\n]\n},\n{\n\"$or\": [\n{\"core or excisional biopsy from soft tissue\": true},\n{\"bone biopsy sample\": true}\n]\n},\n{\"ECOG performance status\": {\"$in\": [0, 1]}}\n]\n},\n{\n\"$not\": {\n\"$or\": [\n{\"additional malignancy\": true},\n{\"active autoimmune disease\": true},\n{\"immunodeficiency or chronic systemic steroid therapy\": true},\n{\"major surgery or gastrointestinal disorder\": true},\n{\"active infection\": true},\n{\"pneumonitis or interstitial lung disease\": true},\n{\"active viral infections\": true},\n{\"CNS metastases or carcinomatous meningitis\": true},\n{\"hypersensitivity or seizure history\": true},\n{\"loss of consciousness or blood pressure abnormalities\": true},\n{\"bradycardia on ECG\": true},\n{\"prostate cancer progression on ketoconazole\": true},\n{\"prior treatment with certain agents\": true},\n{\"prior therapy with radium or chemotherapy\": true},\n{\"prior anti-cancer monoclonal antibody\": true},\n{\"use of herbal products or recent vaccination\": true},\n{\"participation in other studies or allogenic transplant\": true}\n]\n}\n}\n]\n}\n}", "nctId": "NCT03834493", "title": "A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)"}